The Multifaceted Role of Extracellular Vesicles in Triple Negative Breast Cancer
Open Access
- 3 July 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 5976
Abstract
Triple negative breast cancer (TNBC) is an aggressive and heterogeneous subtype of breast cancer characterized by the absence of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), resulting in limited options for targeted therapy and high rates of metastasis, recurrence and death. Extracellular vesicles (EVs) have emerged as central mediators of TNBC pathophysiology, functioning as key intercellular communication vehicles transporting oncogenic proteins, nucleic acids, lipids, and metabolites. These EV-mediated interactions promote tumor microenvironment (TME) remodeling, immune evasion, metastatic niche formation, and therapeutic resistance. Given their stability, accessibility, and molecular complexity, EVs also represent promising diagnostic and prognostic biomarkers for TNBC. Advances in isolation and molecular profiling technologies have enabled the identification of EV-associated signatures that predict therapeutic response and stratify patient risk. Beyond their utility as biomarkers, EVs are rapidly emerging as therapeutic targets and delivery platforms, demonstrating efficacy in transporting chemotherapeutics, RNA-based therapeutics, immune modulators, and photosensitizers with enhanced targeting specificity and therapeutic efficiency. Collectively, EVs play a multifaceted role in TNBC biology, serving simultaneously as drivers of disease progression, minimally invasive biomarkers, and versatile therapeutic vehicles. The integration of EV-centered diagnostics, multi-omic profiling, and engineered therapeutics holds significant potential to transform TNBC management and advance precision oncology for this challenging breast cancer subtype.Keywords
Funding Information
- Florida Cancer Innovative Fund (25C08)
- College of Graduate Studies Open Access Publishing Fund
- Jordan University of Science and Technology
- Goldwater Scholarship and Excellence in Education Foundation
This publication has 157 references indexed in Scilit:
- Tumor‐Derived CDC37 Inhibits Antigen Cross‐Presentation in Dendritic Cells and Impairs Anti‐Tumor Immunity in Breast CancerAdvanced Science, 2025
- Targeting Reticulin 4 (RTN4) Within Small Extracellular Vesicles Combats Metastasis and Reinforces Immunotherapy in Triple‐Negative Breast CancerJournal of Extracellular Vesicles, 2025
- Decoy Extracellular Vesicles Overcome Triple‐Negative Breast Cancer Heterogeneity via Membrane‐Cytoplasm‐Mitochondria Cascade TargetingAdvanced Science, 2025
- Extracellular Vesicle Proteome Analysis Improves Diagnosis of Recurrence in Triple‐Negative Breast CancerJournal of Extracellular Vesicles, 2025
- Baohuoside I chemosensitises breast cancer to paclitaxel by suppressing extracellular vesicle/CXCL1 signal released from apoptotic cellsJournal of Extracellular Vesicles, 2024
- Biointerface‐Engineered Hybrid Nanovesicles for Targeted Reprogramming of Tumor MicroenvironmentAdvanced Materials, 2024
- Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approachesJournal of Extracellular Vesicles, 2024
- Extracellular vesicles secreted by triple‐negative breast cancer stem cells trigger premetastatic niche remodeling and metastatic growth in the lungsInternational Journal of Cancer, 2023
- Immunogenic Nanovesicle‐Tandem‐Augmented Chemoimmunotherapy via Efficient Cancer‐Homing Delivery and Optimized Ordinal‐Interval RegimeAdvanced Science, 2022
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007